MX2022015690A - Nanoparticulas lipidicas. - Google Patents

Nanoparticulas lipidicas.

Info

Publication number
MX2022015690A
MX2022015690A MX2022015690A MX2022015690A MX2022015690A MX 2022015690 A MX2022015690 A MX 2022015690A MX 2022015690 A MX2022015690 A MX 2022015690A MX 2022015690 A MX2022015690 A MX 2022015690A MX 2022015690 A MX2022015690 A MX 2022015690A
Authority
MX
Mexico
Prior art keywords
lnp
lipid
present
lipid nanoparticles
specifically
Prior art date
Application number
MX2022015690A
Other languages
English (en)
Inventor
Koker Stefaan De
Sanne Bevers
Sander Alexander Antonius Kooijmans
Raymond Michael Schiffelers
Original Assignee
Etherna Immunotherapies Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Etherna Immunotherapies Nv filed Critical Etherna Immunotherapies Nv
Publication of MX2022015690A publication Critical patent/MX2022015690A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

La presente invención se refiere al campo de las nanopartículas lipídicas (LNP); más específicamente comprende un lípido ionizable, un fosfolípido, un esterol, un lípido PEG y uno o más ácidos nucleicos. Las LNPs de la presente invención se caracterizan por comprender menos de aproximadamente 1 mol % de un lípido C14-PEG2000; así como porcentajes particulares de otros lípidos. La presente invención proporciona el uso de las LNPs para la administración inmunogénica de moléculas de ácido nucleico, específicamente ARNm; haciéndolos así altamente adecuados para su uso en vacunas, tales como para el tratamiento del cáncer o enfermedades infecciosas. Finalmente, se proporcionan métodos para preparar dichas LNPs.
MX2022015690A 2020-06-11 2021-06-11 Nanoparticulas lipidicas. MX2022015690A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20179435 2020-06-11
EP21160384 2021-03-03
PCT/EP2021/065856 WO2021250263A1 (en) 2020-06-11 2021-06-11 Lipid nanoparticles

Publications (1)

Publication Number Publication Date
MX2022015690A true MX2022015690A (es) 2023-02-22

Family

ID=76355521

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015690A MX2022015690A (es) 2020-06-11 2021-06-11 Nanoparticulas lipidicas.

Country Status (11)

Country Link
EP (1) EP4164596A1 (es)
JP (1) JP2023545886A (es)
KR (1) KR20230050313A (es)
CN (1) CN116133640A (es)
AU (1) AU2021286911A1 (es)
BR (1) BR112022025217A2 (es)
CA (1) CA3186776A1 (es)
IL (1) IL298765A (es)
MX (1) MX2022015690A (es)
WO (1) WO2021250263A1 (es)
ZA (1) ZA202300131B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023220746A1 (en) * 2022-05-13 2023-11-16 Corner Therapeutics, Inc. Mrna encoding a constitutively-active cyclic gmp-amp synthase and lipid delivery vehicles for same
CN114869859A (zh) * 2022-06-02 2022-08-09 深圳厚存纳米药业有限公司 一种核酸纳米粒复合物及其制备方法
WO2024136254A1 (ko) * 2022-12-20 2024-06-27 (주)인벤티지랩 저농도 이온화 지질을 포함하는 지질나노입자 및 이의 제조 방법
CN115998714B (zh) * 2023-03-20 2023-06-30 威瑞生物科技(昆明)有限责任公司 一种脂质纳米颗粒、递送系统及递送系统的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012267578B2 (en) * 2011-06-08 2017-04-20 Translate Bio, Inc. Cleavable lipids
EP4036241A1 (en) * 2013-10-22 2022-08-03 Translate Bio, Inc. Cns delivery of mrna and uses thereof
EP3336192B1 (en) 2013-11-12 2021-12-08 Vrije Universiteit Brussel Rna transcription vector and uses thereof
WO2016118725A1 (en) * 2015-01-23 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
CA3088485A1 (en) * 2018-01-18 2019-07-25 Etherna Immunotherapies Nv Lipid nanoparticles

Also Published As

Publication number Publication date
WO2021250263A1 (en) 2021-12-16
EP4164596A1 (en) 2023-04-19
IL298765A (en) 2023-02-01
ZA202300131B (en) 2023-10-25
CN116133640A (zh) 2023-05-16
KR20230050313A (ko) 2023-04-14
AU2021286911A1 (en) 2023-02-09
JP2023545886A (ja) 2023-11-01
CA3186776A1 (en) 2021-12-16
BR112022025217A2 (pt) 2023-01-03

Similar Documents

Publication Publication Date Title
MX2022009018A (es) Nanoparticulas lipidas.
ZA202300131B (en) Lipid nanoparticles
Liang et al. Development and delivery systems of mRNA vaccines
Aldosari et al. Lipid nanoparticles as delivery systems for RNA-based vaccines
Gote et al. A comprehensive review of mRNA vaccines
Reichmuth et al. mRNA vaccine delivery using lipid nanoparticles
US20210322573A1 (en) Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
CN111971066A (zh) 脂质纳米颗粒
Zhang et al. Modification of lipid-based nanoparticles: An efficient delivery system for nucleic acid-based immunotherapy
JP2010507361A (ja) 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸
WO2020070040A1 (en) Rna particles comprising polysarcosine
WO2016045732A1 (en) Stable formulations of lipids and liposomes
WO2020069718A1 (en) Rna particles comprising polysarcosine
Boloix et al. Engineering pH‐Sensitive Stable Nanovesicles for Delivery of MicroRNA Therapeutics
CA3172600A1 (en) Rna particles comprising polysarcosine
WO2022152141A3 (en) Polymer conjugated lipid compounds and lipid nanoparticle compositions
WO2023205424A3 (en) Lipid compositions and methods for nucleic acid delivery
Bolhassani Lipid-based delivery systems in development of genetic and subunit vaccines
ZA202305909B (en) Lipid compounds and lipid nanoparticle compositions
Desai et al. Nanoadjuvants: promising bioinspired and biomimetic approaches in vaccine innovation
AU2008230379B2 (en) Prompt nucleic acid delivery carrier composition
CN117915958A (zh) 作为在基因递送中的非病毒载体的树枝状结构
Aldosari et al. Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines. Pharmaceutics 2021, 13, 206
US20230355526A1 (en) Lipid compositions comprising polynucleotide antigens
WO2023057935A1 (en) Lipid nanoparticle comprising a nucleic acid-binding protein